Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin

Intervirology

Volumn 52, Issue 5, 2009, Pages 247-251

  Elefsiniotis, I S ^a   Vezali, E ^a   Mihas, C ^a   Saroglou, G ^a  

^a Hepatology Unit   (Greece)

Author keywords

Early virological response; Genotype 4; Hepatitis C; PEG interferon; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGE DISTRIBUTION; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RESPONSE; EGYPT; ETHNICITY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROBIAL KINETICS; PREDICTION; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; VIRUS LOAD;

ADULT; ANIMALS; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RATS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 67650132966     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000228548     Document Type: Article

References (18)

1. McHutchinson JG, Gordon SC, Schiff ER, et al: Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.
2. Lai MY, Kao JH, Yang PM, et al: Long-term efficacy of ribavirin plus interferon alpha in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307-1312.
3. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19: 1-46.
4. Hadziyannis SJ, Sette H Jr, Morgan TR, et al: Peginterferon-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
5. Manns MP, McHutchinson JG, Gordon SC, et al: Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358; 958-965.
6. Fried MW, Shiffman ML, Reddy KR, et al: Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
7. Heathcote EJ, Shiffman ML, Cooksley GE, et al: Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-1680.
8. Kamal SM, Nasser IA: Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology 2008; 47: 1371-1383.
9. Katsoulidou A, Sypsa V, Tassopoulos NC, et al: Molecular epidemiology of HCV in Greece: temporal trends in HCV genotypespecific incidence and molecular characterization of genotype 4 isolates. J Viral Hepat 2006; 13: 19-27.
10. Savvas S, Koskinas J, Sinani C, et al: Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece. J Viral Hepat 2005; 12: 551-557.
11. Diago M, Hassanein T, Rodés J, et al: Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-2a and ribavirin. Ann Intern Med 2004; 140: 72-73.
12. Ishak K, Baptista A, Bianchi L, et al: Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
13. Kamal SM, El Kamary SS, Shardell MD, et al: Pegylated interferon-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virological response. Hepatology 2007; 46: 1732-1740.
14. Hasan F, Asker H, Al-Khaldi J, et al: Peginterferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004; 99: 1733-1737.
15. Kamal SM, El Tawil AA, Nakano T, et al: Peginterferon alpha-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54: 858-866.
16. Roulot D, Bourcier V, Grando V, et al; Observational VHC4 Study Group: Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007; 14: 460-467.
17. Tarantino G, Conca P, Sorrentino P, Ariello M: Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. J Gastroenterol Hepatol 2006; 21: 1266-1268.
18. El-Zayadi AR, Attia M, Barakat EM, et al: Response of HCV genotype 4 naïve patients to 24 weeks of PEG-IFNa2b/ribavirin or induction dose IFNa2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol 2005; 100: 2447-2452.